Watson Pharmaceuticals has received FDA approval on its abbreviated new drug application for a generic version of testosterone gel 1% CIII.
Watson Pharmaceuticals has received FDA approval on its abbreviated new drug application for a generic version of testosterone gel 1% CIII. The drug is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
